Biocon expands Sandoz partnership to sell biosimilars in Australia newindianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newindianexpress.com Daily Mail and Mail on Sunday newspapers.
Merck's Keytruda again bags industry-first cervical cancer nod—with limitation fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Celltrion Healthcare, Celltrion Group’s overseas sales unit, announced Tuesday that Vegzelma, Celltrion’s biosimilar referencing Roche's Avastin (bevacizumab), has been listed as a preferred drug on a formulary managed by Ventegra. “Through Ventegra's proprietary formulary program, which covers 13 million members in the US, Vegzelma will be able to increase its share in the US bevacizumab .
Tempest Therapeutics (NASDAQ: TPST) experienced a remarkable market upswing of over 2,800%, showcasing one of the most substantial gains this year for a once tiny biotech company trading on the Nasdaq. The surge is undeniably tied to their recent press release. However, decoding the significance of this update can be puzzling for everyday investors who